IP Library › Granted Patent US 9,108,964
Granted Patent B2
US 9,108,964 · App. 14/154,885 · Granted Aug 18, 2015

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Inventors: Frank Himmelsbach (Mittelbiberach, DE); Elke Langkopf (Biberach an der Riss, DE); Matthias Eckhardt (Biberach an der Riss, DE); Roland Maier (Biberach an der Riss, DE)
Assignee: Boehringer Ingelheim International GmbH
C07D473/04C07D473/06C07D473/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,108,964
App. No.
14/154,885
Granted
Aug 18, 2015
Kind
B2
Abstract

The present invention relates to substituted xanthines of general formula wherein R 1 to R 3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Claims (19)

1. A compound of formula (III)

wherein

R 1 is 4-methyl-2-quinazolinylmethyl,

R 2 is methyl, and

R 3 is 2-butyn-1-yl.

2. 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine.

3. 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine.

4. A process for preparing a compound of formula (I),

the process comprising deprotecting a compound of formula (III)

wherein

R 1 is 4-methyl-2-quinazolinylmethyl,

R 2 is methyl, and

R 3 is 2-butyn-1-yl.

5. The process according to claim 4 , wherein the tert.-butyloxycarbonyl group is cleaved by treatment with an acid or by treatment with bromotrimethylsilane or iodotrimethylsilane, optionally using a solvent at temperatures between 0 and 80° C.

6. The process according to claim 5 , wherein the acid is trifluoroacetic acid or hydrochloric acid.

7. The process according to claim 5 , wherein the solvent is selected from the group consisting of methylene chloride, ethyl acetate, dioxane, methanol, isopropanol and diethyl ether.

8. A process for preparing a pharmaceutical composition comprising the compound of formula (I) of claim 4 , the process comprising:

preparing the compound of formula (I) according to the process of claim 4 ; and

combining the compound of formula (I), optionally in combination with an additional active substance, with one or more inert carriers and/or diluents into a galenic preparation selected from the group consisting of a plain or coated tablet, capsule, powder, suspension and suppository.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 035772/0451 →
Priority Claims (2)
DE 102 38 243 · Aug 21, 2002 · national
DE 103 12 353 · Mar 20, 2003 · national
Continuity (6)
Continuation 13448495 · Apr 17, 2012
Continuation 12143128 · Jun 20, 2008
Continuation 10639036 · Aug 12, 2003
Provisional Application 60461752 · Apr 10, 2003
Provisional Application 60409312 · Sep 9, 2002
Related Publication 20140128604A1 · May 8, 2014